Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 8/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23908867 | 0.95 | S1PR2 (0.61) | S1PR2SMN1; SMN2AKR1B1GLAMAPT | |
| SCHEMBL23966599 | 0.91 | S1PR2 (0.51) | S1PR2SMN1; SMN2AKR1B1MAPT | |
| SCHEMBL23966649 | 0.90 | S1PR2 (0.59) | S1PR2SMN1; SMN2GLAMEN1KMT2A | |
| SCHEMBL23908880 | 0.89 | S1PR2 (0.63) | S1PR2SMN1; SMN2AKR1B1GLAMAPT | |
| SCHEMBL23966675 | 0.88 | S1PR2 (0.54) | S1PR2SMN1; SMN2AKR1B1GLAMEN1 | |
| SCHEMBL23908794 | 0.88 | S1PR2 (0.62) | S1PR2SMN1; SMN2AKR1B1GLAMEN1 | |
| SCHEMBL23908929 | 0.86 | S1PR2 (0.60) | S1PR2SMN1; SMN2AKR1B1GLAMEN1 | |
| SCHEMBL23908752 | 0.85 | S1PR2 (0.65) | S1PR2SMN1; SMN2AKR1B1GLAMEN1 | |
| SCHEMBL23908913 | 0.85 | S1PR2 (0.63) | S1PR2SMN1; SMN2AKR1B1GLAMEN1 | |
| SCHEMBL23966611 | 0.85 | S1PR2 (0.53) | S1PR2SMN1; SMN2AKR1B1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3649119-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GALAPAGOS NV (BE) | 2021-11-03 | — | — | EP | disclosed |